S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
New York goes dark, then America. (Ad)
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The "Smart Money" Is Ready for May 1st Are You? (Ad)
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
New York goes dark, then America. (Ad)
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The "Smart Money" Is Ready for May 1st Are You? (Ad)
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
New York goes dark, then America. (Ad)
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The "Smart Money" Is Ready for May 1st Are You? (Ad)
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
New York goes dark, then America. (Ad)
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The "Smart Money" Is Ready for May 1st Are You? (Ad)
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Free Trial
NASDAQ:DRUG

Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)
Free DRUG Stock Alerts
$1.12
-0.06 (-5.08%)
(As of 04/19/2024 ET)
Compare
Today's Range
$1.11
▼
$1.17
50-Day Range
$1.11
▼
$1.96
52-Week Range
$1.09
▼
$6.44
Volume
5,974 shs
Average Volume
21,483 shs
Market Capitalization
$4.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
DRUG stock logo

About Bright Minds Biosciences Stock (NASDAQ:DRUG)

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

DRUG Stock Price History

DRUG Stock News Headlines

April 10, 2024 | americanbankingnews.com
Bright Minds Biosciences (NASDAQ:DRUG) Trading 5.8% Higher
January 12, 2024 | msn.com
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
April 20, 2024 | Banyan Hill Publishing (Ad)
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
December 6, 2023 | finance.yahoo.com
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
November 12, 2023 | msn.com
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023 | finance.yahoo.com
Bright Minds Biosciences Inc. (DRUG.CN)
October 25, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG) Dividends: History, Yield and Dates
August 18, 2023 | seekingalpha.com
DRUG Bright Minds Biosciences Inc.
April 20, 2024 | Banyan Hill Publishing (Ad)
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
August 8, 2023 | msn.com
Bright Minds stock rallies ahead of conference call to discuss Phase 1 data
August 8, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
August 7, 2023 | msn.com
Bright Minds reports results from trial to treat refractory epilepsies
July 24, 2023 | benzinga.com
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
July 20, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
July 12, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Short Interest Report
July 11, 2023 | msn.com
Bright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ Compliance
July 11, 2023 | finanznachrichten.de
Bright Minds Biosciences: Bright Minds Announces Effective Date of Share Consolidation
June 22, 2023 | finanznachrichten.de
Bright Minds Biosciences: Bright Minds Announces Proposed Share Consolidation
June 22, 2023 | finance.yahoo.com
Bright Minds Announces Proposed Share Consolidation
May 16, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Earnings Estimates, EPS, and Revenue
April 20, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Analyst Ratings, Price Targets, Predictions
April 19, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Trade Ideas
April 19, 2023 | finance.yahoo.com
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
April 10, 2023 | finance.yahoo.com
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
February 27, 2023 | finance.yahoo.com
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
February 8, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
January 27, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
See More Headlines
Receive DRUG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
4/20/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRUG
CUSIP
N/A
CIK
1827401
Web
brightmindsbio.com
Phone
64-7407-2515
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-91.83%
Return on Assets
-83.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.01
Quick Ratio
8.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
4,430,000
Free Float
2,542,000
Market Cap
$4.96 million
Optionable
Not Optionable
Beta
1.41
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Ian McDonald (Age 35)
    Co-Founder, CEO, President & Director
  • Mr. Ryan E. S. K. Cheung B.Com. (Age 46)
    CA, CPA, Chief Financial Officer
    Comp: $88.2k
  • Dr. Jan Torleif Pedersen M.Sc. (Age 59)
    Ph.D., Chief Science Officer & Director
    Comp: $179.01k
  • Dr. Mark A. Smith M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Comp: $240.74k
  • Dr. Emer Leahy M.B.A. (Age 57)
    Ph.D., Consultant

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed in 2024?

Bright Minds Biosciences' stock was trading at $1.43 on January 1st, 2024. Since then, DRUG stock has decreased by 21.7% and is now trading at $1.12.
View the best growth stocks for 2024 here.

When is Bright Minds Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our DRUG earnings forecast.

How were Bright Minds Biosciences' earnings last quarter?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its quarterly earnings data on Monday, February, 12th. The company reported ($0.32) EPS for the quarter.

When did Bright Minds Biosciences' stock split?

Shares of Bright Minds Biosciences reverse split before market open on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRUG) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends